Brief: Vanda, Anaptys Bio Enter into Global Deal TO Develop & Market Imsidolimab

AnaptysBio

03/02/2025 12:49

Feb 3 (Reuters) - AnaptysBio Inc  ANAB.O :
    * VANDA PHARMACEUTICALS AND ANAPTYS ANNOUNCE EXCLUSIVE
GLOBAL
LICENSE AGREEMENT FOR VANDA TO DEVELOP AND COMMERCIALIZE
IMSIDOLIMAB, AN IL-36R ANTAGONIST
    * VANDA PHARMACEUTICALS INC: VANDA EXPECTS TO IMMEDIATELY
BEGIN
PREPARING BLA AND MAA APPLICATIONS FOR US AND EU
    * VANDA PHARMACEUTICALS INC: ANAPTYS TO RECEIVE $15 MILLION
FROM
VANDA, COMPRISED OF A $10 MILLION UPFRONT PAYMENT AND $5 MILLION
FOR EXISTING DRUG SUPPLY
    * VANDA PHARMACEUTICALS INC: ANAPTYS TO RECEIVE A 10%
ROYALTY ON
GLOBAL NET SALES OF IMSIDOLIMAB

Source text:  ID:nPn5brdDta 
Further company coverage:  ANAB.O 

 ((Reuters.Briefs@thomsonreuters.com;))